Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
American Journal of Hematology · 2025-12 · 100 (12) · 2293-2304
DOI: 10.1002/ajh.70083 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, online erschienen am 24.09.2025. Verfasst von Fabio Guolo und 56 weiteren Autor:innen. Beteiligte Einrichtung: University of Genoa, Department of Internal Medicine (DiMI), Genoa, Italy. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (allo‐HSCT), and the activity of CPX‐351 in specific s‐AML subgroups are unclear. To evaluate these aspects, a total of 513 s‐AML patients (median age 65.6 years, 19–79) treated with CPX‐351 were retrospectively analyzed. Complete remission (CR) rate after induction was 297/513 (58%), increasing to 340/513 (66%) after cycle 2. Among the 340 responding patients, 118 (34.7%), 137 (40.3%), and 85 (25%) received none, one, or two consolidation cycles of CPX‐351, respectively. Overall, 230/513 patients (48.8%) received allo‐HSCT. Median follow up was 23.66 months and median overall survival (OS) was 16.23 months. Patients with mutated NPM 1 or with ELN 2017 favorable risk ( p < 0.05) had a significantly longer OS ( p < 0.05). In a landmark analysis, receiving allo‐HSCT was associated with a longer survival (Median OS not reached vs. 16.3 months for patients receiving or not receiving allo‐HSCT, p < 0.05). Completion of all allowed CPX‐351 cycles was beneficial only in patients not proceeding to transplant ( p < 0.05), whereas in transplanted patients additional CPX‐351 cycles did not improve outcome. Our analysis suggests that also s‐AML patients with NPM1 mutations and those belonging to the ELN 2017 favorable risk category benefit from CPX‐351. In eligible patients, allo‐HSCT should be performed as soon as a CR is achieved, whereas patients not undergoing transplant benefit from a complete CPX‐351 schedule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Genoa, Department of Internal Medicine (DiMI), Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino, Dipartimento di Oncologia ed Ematologia, Genoa, Italy.
- Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Ematologia e TCSE, Rome, Italy.
- Università di Perugia, Ospedale "Santa Maria della Misericordia", Dipartimento di Medicina e Chirurgia, Perugia, Italy.
- ASST Papa Giovanni XXIII, Hematology and Bone Marrow Transplant Unit, Bergamo, Italy.
- Università degli Studi di Napoli "Federico II", Naples, Italy.
ORCID-Profile: Fabio Guolo, Luana Fianchi, Maria Paola Martelli, Federico Lussana, Paola Minetto, Patrizia Chiusolo, Massimo Breccia, Luca Maurillo, Nicola Stefano Fracchiolla, Calogero Vetro, Alessandra Sperotto, Patrizia Zappasodi, Erika Borlenghi, Michelina Dargenio, Marco Cerrano, Daniela Cilloni, Alessandro Isidori, Carola Riva, Giovanni Marconi, Samuele Gatani, Salvatore Perrone, Francesco Mannelli, Roberto Cairoli, Felicetto Ferrara, Livio Pagano, Adriano Venditti
Zitieren
APA
Guolo, F., Fianchi, L., Martelli, M. P., Lussana, F., Grimaldi, F., Pilo, F., Rondoni, M., Filì, C., Minetto, P., Capelli, D., Chiusolo, P., Breccia, M., Mastaglio, S., Bernardi, M., Bocchia, M., Fumagalli, M., Galimberti, S., Mancini, V., Piccioni, A. L., …, & Todisco, E. (2025). Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. American Journal of Hematology, 100(12), 2293-2304. https://doi.org/10.1002/ajh.70083
Vancouver
Guolo F, Fianchi L, Martelli MP, Lussana F, Grimaldi F, Pilo F, et al. Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. American Journal of Hematology. 2025;100(12):2293-2304. doi:10.1002/ajh.70083
BibTeX
@article{Guolo2025,
author = {Guolo, Fabio and Fianchi, Luana and Martelli, Maria Paola and Lussana, Federico and Grimaldi, Francesco and Pilo, Federica and Rondoni, Michela and Filì, Carla and Minetto, Paola and Capelli, Debora and Chiusolo, Patrizia and Breccia, Massimo and Mastaglio, Sara and Bernardi, Massimo and Bocchia, Monica and Fumagalli, Monica and Galimberti, Sara and Mancini, Valentina and Piccioni, Anna Lisa and Maurillo, Luca and Fracchiolla, Nicola Stefano and Palmieri, Raffaele and Vetro, Calogero and Papayannidis, Cristina and Brunetti, Lorenzo and Sperotto, Alessandra and Gigli, Federica and Zappasodi, Patrizia and Mulé, Antonino and Patti, Caterina and Borlenghi, Erika and Dargenio, Michelina and Lessi, Federica and Cerrano, Marco and Cilloni, Daniela and Isidori, Alessandro and Lunghi, Monia and Alati, Caterina and Gurrieri, Carmela and Riva, Carola and Marconi, Giovanni and Lotesoriere, Ivana and Gatani, Samuele and Scattolin, Anna Maria and Caizzi, Manuela and Perrone, Salvatore and Billio, Atto and Gherlinzoni, Filippo and Mannelli, Francesco and Gottardi, Michele and Cairoli, Roberto and Candoni, Anna and Ferrara, Felicetto and Pagano, Livio and Lemoli, Roberto Massimo and Venditti, Adriano and Todisco, Elisabetta},
title = {Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {12},
pages = {2293--2304},
doi = {10.1002/ajh.70083}
}
EUVIMED